MDL Track
MDL 3094
S.D.N.Y. (MDL 3094); S.D. Fla. (MDL 2994)
Environmental · claims that chronic benzene exposure from consumer products, industrial workplaces, or contaminated environments causes leukemia, lymphoma, and other blood cancers
Defendant
The 3M Company
MDL / Track
2 tracked MDLs
S.D.N.Y. (MDL 3094); S.D. Fla. (MDL 2994)
Judge
Judge Analisa Torres (MDL 3094)
Plaintiffs
4,200+ pending in MDL 2994 sunscreen litigation
Bellwether / Trial
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
Benzene exposure litigation in 2026 proceeds on two active tracks: historic occupational claims against petroleum and chemical majors, and a consumer-product wave anchored by 2021-2024 recalls of aerosol sunscreens, antiperspirants, dry shampoos, and hand sanitizers. The Ninth Circuit revived consumer-product standing in Bowen v. Energizer Holdings, Inc., No. 23-55116 (9th Cir. Oct. 1, 2024), reversing a Central District of California dismissal and holding that economic-injury standing does not require proving FDA noncompliance. In the occupational track, Philadelphia Judge Carmella Jacquinto upheld a $725.5 million verdict against ExxonMobil in May 2025, rejecting excessiveness challenges. General causation for benzene-linked malignancies — AML, CML, ALL, NHL, MDS, aplastic anemia, and multiple myeloma — is essentially uncontested; disputes center on specific causation, dose, and statute of limitations.
Causation Theory
Benzene is a WHO/IARC Group 1 carcinogen with established hematotoxicity and leukemogenic mechanisms through metabolite-induced chromosomal damage and bone-marrow suppression. The consumer-product contamination pathway was identified by Valisure independent laboratory testing beginning in 2021, which detected benzene in aerosol personal care products at levels exceeding FDA interim limits, with some Johnson & Johnson sunscreen samples above 6 ppm. A 2023 study in Science of The Total Environment (Pal et al.) found benzene in 80% of 50 U.S. sunscreens at mean 45.8 ng/g, with cancer risk exceeding the 1.0 × 10⁻⁶ benchmark in 44% of products for children/teenagers and 38% for adults. Dermal absorption is enhanced by sunscreen application over large body-surface areas, and inhalation from aerosol propellants adds exposure. FDA guidance states benzene "should not be employed" in drug products; its 2 ppm interim limit applies only when use is "unavoidable" for significant therapeutic advance.
Case Management Orders
Litigation status
Benzene litigation operates on parallel federal tracks without unified consolidation. MDL 3094 (In re: Benzene Contamination Litigation) sits before Judge Analisa Torres in the Southern District of New York, consolidating consumer-product claims. Separately, MDL 2994 in the Southern District of Florida handles sunscreen-specific personal injury claims with bellwether trials scheduled for late 2026. A federal judge dismissed a L'Oréal benzene class action on September 21, 2026, rejecting claims over CeraVe and La Roche-Posay acne products.
MDL Track
MDL 3094
S.D.N.Y. (MDL 3094); S.D. Fla. (MDL 2994)
MDL Track
MDL 2994
S.D.N.Y. (MDL 3094); S.D. Fla. (MDL 2994)
State Court Activity
Active dockets in Missouri, Pennsylvania, California, and North Carolina; Dickerson v. CRC Industries preserved disease claims under North Carolina repose statutes
Geographic exposure
Approximately 119 US refineries subject to EPA Petroleum Refinery Sector Rule fenceline monitoring since 2018; national median net benzene declined to 2 µg/m³ by 2023. Persistent state-level disparities: Gulf Coast refineries (Texas, Louisiana) emit 5× higher benzene than West Coast (California, Washington) despite similar facility capacities. Cancer Alley corridor: 85-mile Mississippi River industrial zone, 150+ petrochemical facilities, 11,000+ residents within two-mile radius of heavy industrial facilities in St. John the Baptist Parish alone.
Statewide refinery mean net benzene concentration of 6.5 µg/m³ (95% CI: 4.6–8.5), highest in nation per 2018–2023 EPA fenceline data; 14 refineries monitored. St. John the Baptist Parish ranks 98th percentile nationally for benzene-related cancer risk per EPA 2024 RSEI model. State v. ExxonMobil, Civil Action No. 742891 (19th JDC, East Baton Rouge Parish), Judge William Morvant, June 5, 2026: $47M judgment for Baton Rouge refinery emissions exceeding permitted thresholds by 340% over 18-month period; EPA Region 6 confirmed fence-line concentrations nine times above risk-based screening level in Reserve and LaPlace neighborhoods.
Statewide refinery mean net benzene concentration of 6.1 µg/m³ (95% CI: 4.8–7.4), second-highest nationally; 28 refineries monitored. Nine of 20 worst benzene polluters nationally located in Texas per 2018–2023 data. Port Arthur fenceline communities at Texas-Louisiana border experience chronic exposure; TotalEnergies Port Arthur refinery ranked third-highest benzene levels nationally. TCEQ long-term exposure limit of 1.4 ppb is 5.8× higher than Minnesota (0.24 ppb) and 47× higher than Massachusetts (0.03 ppb). Channelview community near Houston showed 'significantly greater than expected' leukemia and lymphoma rates per 2025 state data.
Navajo Refinery, Eddy County: highest benzene polluter nationally among 119 refineries studied 2018–2023 per Environmental Defense Fund analysis published April 2026.
Statewide refinery mean net benzene concentration of 1.0 µg/m³ (95% CI: 0.7–1.3), lowest among major refining states; 12 refineries monitored. Consistently lower distribution than national median despite comparable facility capacity.
Statewide refinery mean net benzene concentration of 1.2 µg/m³, second-lowest among major refining states; performance comparable to California with five-fold lower emissions than Gulf Coast refineries.
Sunscreen benzene contamination: 44% of 50 products tested exceeded 1.0 × 10⁻⁶ cancer risk benchmark for children/teenagers; 38% exceeded for adults. Mean benzene concentration 45.8 ng/g (range: 0.007–862 ng/g). Valisure independent screening of 661 sun care products (2020–2021): 192 samples with detectable benzene, 72 samples >2.0 ppm, with maximum concentrations 11.2–23.6 ppm in aerosol formulations per FDA testing. FDA December 2021 alert to manufacturers on contamination risk.
Key defendants
The 3M Company
Role: Manufacturer
Removed to SDNY (1:25-cv-06724) under federal officer jurisdiction; no corporate parent per Rule 7.1 disclosure. Early posture, no dispositive motion activity yet.
Exxon Mobil
Role: Petroleum Refiner
Motion to dismiss denied July 2025 in Dickerson v. CRC Industries (E.D.N.C.); court rejected statute of repose defense for disease-based MDS claims. Exposure now merits-phase.
PBF Energy Inc.
Role: Refinery Operator
Named in N.D. Cal. class action (3:23-cv-06142) with Martinez Refining Co. subsidiary; claims include Clean Air Act violations, medical monitoring, and ultrahazardous activity. Active discovery posture.
Martinez Refining Company LLC
Role: Refinery Subsidiary
Co-defendant with PBF Energy in N.D. Cal. benzene emissions class action; allegations of unreported toxic releases from November 2022 incident. No dismissal motion filed per docket.
| Defendant | Role | Intelligence Note |
|---|---|---|
| The 3M Company | Manufacturer | Removed to SDNY (1:25-cv-06724) under federal officer jurisdiction; no corporate parent per Rule 7.1 disclosure. Early posture, no dispositive motion activity yet. |
| Exxon Mobil | Petroleum Refiner | Motion to dismiss denied July 2025 in Dickerson v. CRC Industries (E.D.N.C.); court rejected statute of repose defense for disease-based MDS claims. Exposure now merits-phase. |
| PBF Energy Inc. | Refinery Operator | Named in N.D. Cal. class action (3:23-cv-06142) with Martinez Refining Co. subsidiary; claims include Clean Air Act violations, medical monitoring, and ultrahazardous activity. Active discovery posture. |
| Martinez Refining Company LLC | Refinery Subsidiary | Co-defendant with PBF Energy in N.D. Cal. benzene emissions class action; allegations of unreported toxic releases from November 2022 incident. No dismissal motion filed per docket. |
Timeline
Valisure Petitions FDA on Benzene in Sunscreens
Independent laboratory Valisure files citizen petition with FDA detecting benzene in sunscreen and after-sun care products, requesting recalls of 40 specific batches. FDA acknowledged petition in interim response dated November 18, 2021, stating it was 'unable to reach a decision' because the petition 'raises complex issues requiring extensive review and analysis.'
J&J Recalls Neutrogena, Aveeno Sunscreens
Johnson & Johnson issues voluntary nationwide recall of five aerosol sunscreen lines after internal testing confirms benzene contamination. Recall covers Neutrogena Beach Defense, Cool Dry Sport, Invisible Daily Defense, Ultra Sheer, and Aveeno Protect + Refresh. Recall becomes foundational event for consumer-product litigation track.
MDL 3015 Formed for J&J Sunscreen Litigation
Judicial Panel on Multidistrict Litigation consolidates cases into MDL No. 3015 (In re: Johnson & Johnson Aerosol Sunscreen Marketing, Sales Practices and Products Liability Litigation), assigned to Judge Anuraag Singhal in the Southern District of Florida. Cases involve consumer fraud, product liability, and failure to warn theories.
MDL 3094 Formed for Benzene Contamination Litigation
JPML creates MDL No. 3094 (In re: Benzene Contamination Litigation) in the Southern District of New York, assigned to Judge Analisa Torres, consolidating consumer-product benzene cases beyond the J&J sunscreen docket.
$725.5M Verdict Against ExxonMobil in AML Case
Philadelphia jury awards $725.5 million against ExxonMobil in Gill v. Exxon Mobil Corp., finding company failed to warn about benzene in gasoline and solvents; trial court later adds $90.5 million in delay damages for total of $816 million. Plaintiff, former gas station mechanic exposed 1975-1980, diagnosed with leukemia. ExxonMobil appeals.
Ninth Circuit Revives Banana Boat Standing
Ninth Circuit reverses dismissal in Bowen v. Energizer Holdings, Inc., No. 23-55116 (9th Cir. Oct. 1, 2024), holding that economic injury from overpayment satisfies Article III standing without requiring proof of noncompliance with FDA's 2 ppm benzene guidance. Panel finds district court improperly weighed disputed evidence at pleading stage.
E.D.N.C. Preserves MDS Claims Against Exxon
Judge Louise Flanagan in Dickerson v. CRC Industries, Inc., et al., No. 7:25-cv-00031 (E.D.N.C.), denies Exxon Mobil's motion to dismiss, holding myelodysplastic syndrome claim timely under North Carolina's discovery rule and that state statutes of repose do not apply to latent disease claims. Plaintiff exposed 1955-2006 at Weyerhaeuser facility, diagnosed 2017.
Unilever Dry Shampoo Settlement Denied Preliminary Approval
Proposed $3 million class action settlement with Unilever over benzene-contaminated dry shampoo brands denied preliminary approval by court. Separate $850,000 settlement involving IGK brand products enters payment administration. Procter & Gamble previously resolved Old Spice and Secret deodorant claims for $8 million in 2022; Beiersdorf paid $2 million to settle Coppertone sunscreen benzene claims in 2023.
Statute of limitations
FDA 2 ppm guidance for unavoidable benzene in drugs distinguishes sunscreen as elective cosmetic use—supports failure-to-warn theories. IARC March 2025 reclassification of automotive gasoline as Group 1 carcinogen strengthens causation evidence. No nationwide tolling agreement identified.
North Carolina
3 years from diagnosis
Rule: Disease claims accrue at diagnosis, not exposure; statutes of repose held inapplicable to latent disease claims per Dickerson v. CRC Industries, Inc., et al., E.D.N.C. July 2025 (citing Dunn v. Pacific Employers Insurance Co., 1992; Wilder v. Moore, 1994; Stahle v. CTS Corp., 4th Cir.)
Discovery: Accrual at diagnosis of benzene-related illness (MDS, AML, aplastic anemia), not at end of exposure
Federal court rejected 6- and 10-year repose defenses under N.C. Gen. Stat. §§ 1-50(a)(6) and 1-52(16). Exposure ending in 2006; diagnosis 2017; filing 2019 held timely.
California
2 years from discovery of injury
Rule: Discovery rule applies; Bowen v. Energizer Holdings, Inc., 2024 WL 4352496 (9th Cir. Oct. 1, 2024) recognized Article III standing for benzene sunscreen consumer claims
9th Circuit remanded for merits determination on safety allegations; consumer benzene exposure claims remain viable.
Florida
4 years from injury
Rule: Discovery rule applies for latent diseases; MDL 2994 (Benzene Sunscreen) centralized in S.D. Fla.
Discovery: Accrual tied to diagnosis or when disease becomes apparent, not exposure date
MDL 2994 active as of January 2026. Personal injury track proceeding to trial 2026-2027. Class action settlement largely resolved; individual injury claims remain viable. Screen for: AML, MDS, leukemia diagnoses with sunscreen use 2021-2022 recall period.
Illinois
2 years from discovery of injury
Rule: 735 ILCS 5/13-202; discovery rule applies for toxic torts with latency periods
Discovery: Accrual when plaintiff knows or reasonably should know of injury and its cause
Pennsylvania
2 years from discovery of injury
Rule: 42 Pa.C.S. § 5524(2); discovery rule applies for latent diseases
Discovery: Accrual upon discovery of injury and factual basis for causation
Dickerson originally filed in Philadelphia County 2019; dismissed for jurisdictional reasons. North Carolina refile held timely.
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| North Carolina | 3 years from diagnosis | Disease claims accrue at diagnosis, not exposure; statutes of repose held inapplicable to latent disease claims per Dickerson v. CRC Industries, Inc., et al., E.D.N.C. July 2025 (citing Dunn v. Pacific Employers Insurance Co., 1992; Wilder v. Moore, 1994; Stahle v. CTS Corp., 4th Cir.) | Accrual at diagnosis of benzene-related illness (MDS, AML, aplastic anemia), not at end of exposure | Federal court rejected 6- and 10-year repose defenses under N.C. Gen. Stat. §§ 1-50(a)(6) and 1-52(16). Exposure ending in 2006; diagnosis 2017; filing 2019 held timely. |
| California | 2 years from discovery of injury | Discovery rule applies; Bowen v. Energizer Holdings, Inc., 2024 WL 4352496 (9th Cir. Oct. 1, 2024) recognized Article III standing for benzene sunscreen consumer claims | — | 9th Circuit remanded for merits determination on safety allegations; consumer benzene exposure claims remain viable. |
| Florida | 4 years from injury | Discovery rule applies for latent diseases; MDL 2994 (Benzene Sunscreen) centralized in S.D. Fla. | Accrual tied to diagnosis or when disease becomes apparent, not exposure date | MDL 2994 active as of January 2026. Personal injury track proceeding to trial 2026-2027. Class action settlement largely resolved; individual injury claims remain viable. Screen for: AML, MDS, leukemia diagnoses with sunscreen use 2021-2022 recall period. |
| Illinois | 2 years from discovery of injury | 735 ILCS 5/13-202; discovery rule applies for toxic torts with latency periods | Accrual when plaintiff knows or reasonably should know of injury and its cause | — |
| Pennsylvania | 2 years from discovery of injury | 42 Pa.C.S. § 5524(2); discovery rule applies for latent diseases | Accrual upon discovery of injury and factual basis for causation | Dickerson originally filed in Philadelphia County 2019; dismissed for jurisdictional reasons. North Carolina refile held timely. |
Live intelligence
AI litigation brief
Benzene Exposure remains established mass tort with 16 current signals in the accepted feed.
Overview
Benzene litigation operates on parallel federal tracks without unified consolidation. MDL 3094 (In re: Benzene Contamination Litigation) sits before Judge Analisa Torres in the Southern District of New York, consolidating consumer-product claims. Separately, MDL 2994 in the Southern District of Florida handles sunscreen-specific personal injury claims with bellwether trials scheduled for late 2026. A federal judge dismissed a L'Oréal benzene class action on September 21, 2026, rejecting claims over CeraVe and La Roche-Posay acne products.
Key developments
Trajectory
Press and regulatory signals are moving in tandem for Benzene Litigation. The next escalation check is whether these agency actions prompt new PACER filings or MDL scheduling orders.
Editorial intelligence
Track MDL 3094 and MDL 2994 as separate litigation lanes; combining them hides differences in defendants, injuries, and case inventory.
Generated Sep 30, 2026, 10:00 AM UTC
16 events detected
Google News (13)
Judge dismisses L’Oréal benzene contamination lawsuit - Cosmetics Business
Judge Tosses Benzene Class Action Against L’Oréal Over CeraVe, La Roche-Posay Acne Products - lawcommentary.com
L’Oréal Sheds CeraVe, La Roche-Posay Acne Products Benzene Suit - Bloomberg Law News
Gasoline Supplier Files Complaint, Says Coverage Owed For Benzene Exposure Lawsuits - Mealey's
Illinois Federal Judge Allows Negligence, Battery Claims In Benzene Exposure Suit - Mealey's
Exclusive | Walmart continues stocking air freshener packed with cancer-causing benzene: lawsuit - New York Post
CVS Escapes Customer's Generic Mucinex Benzene Suit - Law360
Claim form open: MG217 Shampoo manufacturer agrees to settle benzene class action lawsuit for $1.2 million - Claim Depot
MG217 Shampoo $1.2 Million Benzene Class Action Settlement - Claim Depot
Walgreens, Walmart Can’t Shake Acne Product Benzene Lawsuits - Bloomberg Law News
CeraVe Lawsuit 2026: Payouts (Updated July 2026) - LawFold.com
Berger Montague and Locks Law Firm File Class Action for Residents Affected by Massive Gasoline Leak at Aston, Pa. Chelsea Tank Farm - citybiz.co
CeraVe benzene cancer lawsuit: The truth about the products, the 2026 recall rumours and the risks - Mamabella
No recent PubMed signals. Monitoring is active — this section updates automatically.
This EPA Superfund profile documents the RAM Leather Care Site in Charlotte, NC, a contaminated industrial location where benzene-containing waste from leather processing operations created environmental hazards. The site profile provides evidence of benzene contamination in soil and groundwater, directly relevant to environmental benzene exposure claims linked to blood cancers.
EPA Superfund regulatory on Aug 30 for Benzene Litigation. Regulatory developments can change intake posture and motion practice quickly.
The EPA proposes a cleanup plan for benzene and other chemical contamination at a former pesticide manufacturing Superfund site in New Jersey, where historical benzene exposure poses cancer risks to nearby residents and workers.
EPA News Release regulatory on Jun 15 for Benzene Litigation. Regulatory developments can change intake posture and motion practice quickly.
The EPA is proposing a cleanup plan for the Orlando Gasification Superfund Site, which involves benzene contamination in the environment. This relates to benzene exposure claims as it documents government-recognized benzene contamination requiring remediation, potentially supporting environmental exposure litigation theories.
EPA News Release regulatory on Apr 7 for Benzene Litigation. Regulatory developments can change intake posture and motion practice quickly.
No recent court filing signals. Monitoring is active — this section updates automatically.
No recent legislative signals. Monitoring is active — this section updates automatically.
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
71Score
Court, news, and regulatory activity are elevated
Monitoring
Live
monitoring
Last: Sep 30, 2026, 10:00 AM UTC
Next: —
Source Monitoring
PACER
PACER
Google News
PubMed
EPA
Event feed
16
events detected
AI Brief
Benzene Exposure remains established mass tort with 16 current signals in the accepted feed.
Overview
Benzene litigation operates on parallel federal tracks without unified consolidation. MDL 3094 (In re: Benzene Contamination Litigation) sits before Judge Analisa Torres in the Southern District of New York, consolidating consumer-product claims. Separately, MDL 2994 in the Southern District of Florida handles sunscreen-specific personal injury claims with bellwether trials scheduled for late 2026. A federal judge dismissed a L'Oréal benzene class action on September 21, 2026, rejecting claims over CeraVe and La Roche-Posay acne products.
Key developments
Cosmetics Business news on Sep 21: Judge dismisses L’Oréal benzene contamination lawsuit - Cosmetics Business. ‖ EPA Superfund regulatory on Aug 30: RAM LEATHER CARE SITE | Superfund Site Profile - gov.epa.cfpub.
Generated Sep 30, 2026, 10:00 AM UTC
Tracked MDLs
MDL 3094
S.D.N.Y. (MDL 3094); S.D. Fla. (MDL 2994)
MDL 2994
S.D.N.Y. (MDL 3094); S.D. Fla. (MDL 2994)
← Previous
Baby Food Heavy Metals
Tracks product-liability litigation, FDA enforcement, and neurodevelopmental research tied to toxic heavy metals in commercial baby food products.
Next →
Discord Sexual Abuse
Tracks platform-design liability litigation and policy activity tied to Discord-facilitated grooming, exploitation, and sexual abuse of minors.